{"id":7482,"date":"2025-12-20T01:34:59","date_gmt":"2025-12-19T16:34:59","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4523\/"},"modified":"2026-08-23T13:47:42","modified_gmt":"2026-08-23T04:47:42","slug":"company-4523","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4523\/","title":{"rendered":"EISAI CO LTD"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4523","DATE":"2025-12-22","longName":"Eisai Co., Ltd.","company_name_ja":"\u30a8\u30fc\u30b6\u30a4(\u682a)","fullTimeEmployees":10543,"address":"","phone":"","website":"https:\/\/www.eisai.co.jp","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":4471,"financialCurrency":"","marketCap":1261334,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":136.78,"epsForward":0,"bookValue":0,"totalRevenue":825378000000,"OperatingIncome":44139000000,"operatingMargins":5.3499999999999996,"NetIncome":38558000000,"profitMargins":4.6699999999999999,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":4.29,"recommendationMean":2.5,"recommendationKey":"buy","targetMeanPrice":4482.143,"numberOfAnalystOpinions":13,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:57:54.044820\", \"ticker\": \"4523\", \"ticker_full\": \"4523.T\", \"company_name\": \"EISAI CO LTD\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 0, \"buy\": 4, \"hold\": 8, \"sell\": 0, \"strong_sell\": 1, \"total_analysts\": 13, \"recommendation_key\": \"buy\", \"recommendation_mean\": 2.5}, \"target_prices\": {\"has_data\": true, \"current\": 4828.0, \"high\": 5500.0, \"low\": 3200.0, \"mean\": 4482.143, \"median\": 4450.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": {\"date\": \"2026-08-03\", \"eps_estimate\": 39.33, \"eps_actual\": null, \"surprise_pct\": null}, \"future_count\": 1, \"past_earnings\": [{\"date\": \"2026-05-15\", \"eps_estimate\": 14.57, \"eps_actual\": -11.53, \"surprise_pct\": -179.14}, {\"date\": \"2026-02-09\", \"eps_estimate\": 60.51, \"eps_actual\": 60.94, \"surprise_pct\": 0.7}, {\"date\": \"2025-11-04\", \"eps_estimate\": 49.45, \"eps_actual\": 36.02, \"surprise_pct\": -27.16}, {\"date\": \"2025-08-04\", \"eps_estimate\": 39.33, \"eps_actual\": 51.35, \"surprise_pct\": 30.55}, {\"date\": \"2025-05-14\", \"eps_estimate\": 32.72, \"eps_actual\": 3.37, \"surprise_pct\": -89.7}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 2.18, \"institution_pct\": 55.98, \"major_holders\": [{\"label\": \"\", \"value\": 2.18}, {\"label\": \"\", \"value\": 55.98}, {\"label\": \"\", \"value\": 57.23}, {\"label\": \"\", \"value\": 278.0}], \"institutional_holders\": [{\"holder\": \"Pacer Advisors, Inc.\", \"shares\": 2352, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.0, \"pct_change\": 2.89, \"value\": 11355456}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund\", \"shares\": 7339417, \"date_reported\": \"2026-04-30\", \"pct_held\": 2.52, \"pct_change\": -13.8, \"value\": 35434705276}, {\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 3868323, \"date_reported\": \"2026-04-30\", \"pct_held\": 1.33, \"pct_change\": -0.49, \"value\": 18676263444}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 2561062, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.88, \"pct_change\": 2.59, \"value\": 12364807336}, {\"holder\": \"HARTFORD MUTUAL FUNDS INC\/CT-The Hartford International Value Fund\", \"shares\": 1875361, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.64, \"pct_change\": 10.6, \"value\": 9054242908}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 1860600, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.64, \"pct_change\": 0.0, \"value\": 8982976800}, {\"holder\": \"iShares, Inc.-iShares MSCI Japan ETF\", \"shares\": 1114000, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.38, \"pct_change\": 4.56, \"value\": 5378392000}, {\"holder\": \"Fidelity Concord Street Trust-Fidelity International Index Fund\", \"shares\": 982121, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.34, \"pct_change\": -0.61, \"value\": 4741680188}, {\"holder\": \"iShares Trust-iShares MSCI EAFE ETF\", \"shares\": 909800, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.31, \"pct_change\": -0.79, \"value\": 4392514400}, {\"holder\": \"J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF\", \"shares\": 867800, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.3, \"pct_change\": 9.25, \"value\": 4189738400}, {\"holder\": \"VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Index Fd.\", \"shares\": 615874, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.21, \"pct_change\": 5.05, \"value\": 2973439672}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (A\u00df) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":80,"get_dividend_history_year2":160,"get_dividend_history_year3":160,"get_dividend_history_year4":160,"get_dividend_history_year5":160,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T03:06:37.094379\", \"ticker\": \"4523\", \"ticker_full\": \"4523.T\", \"company_name\": \"EISAI CO LTD\", \"company_info\": {\"name_en\": \"EISAI CO LTD\", \"long_name\": \"Eisai Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.eisai.co.jp\", \"employees\": 10543, \"country\": \"Japan\", \"city\": \"Tokyo\", \"address\": \"4-6-10 Koishikawa\", \"description\": \"Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (A\u00df) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 4841.8, \"deviation\": 1.24, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 4748.6, \"deviation\": 3.23, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 4333.84, \"deviation\": 13.11, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 4549.9, \"deviation\": 7.74, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 825378000000.0, \"revenue_fmt\": \"\u00a58254\u5104\", \"gross_profit\": 634155000000.0, \"gross_profit_fmt\": \"\u00a56342\u5104\", \"operating_income\": 44139000000.0, \"operating_income_fmt\": \"\u00a5441\u5104\", \"ebit\": 56334000000.0, \"ebit_fmt\": \"\u00a5563\u5104\", \"net_income\": 38558000000.0, \"net_income_fmt\": \"\u00a5386\u5104\", \"eps\": 136.78, \"operating_margin\": 5.35, \"total_assets\": 1449113000000.0, \"total_assets_fmt\": \"\u00a51.4T\", \"total_equity\": 898992000000.0, \"total_equity_fmt\": \"\u00a58990\u5104\", \"total_debt\": 186081000000.0, \"total_debt_fmt\": \"\u00a51861\u5104\", \"total_cash\": 245423000000.0, \"total_cash_fmt\": \"\u00a52454\u5104\", \"equity_ratio\": 62.04, \"de_ratio\": 0.21, \"current_ratio\": 2.24, \"operating_cf\": 61323000000.0, \"operating_cf_fmt\": \"\u00a5613\u5104\", \"investing_cf\": -41795000000.0, \"investing_cf_fmt\": \"-\u00a5418\u5104\", \"financing_cf\": -61100000000.0, \"financing_cf_fmt\": \"-\u00a5611\u5104\", \"free_cf\": 20156000000.0, \"free_cf_fmt\": \"\u00a5202\u5104\", \"net_margin\": 4.67, \"roe\": 4.29, \"roa\": 2.66}, {\"year\": 2025, \"revenue\": 789400000000.0, \"revenue_fmt\": \"\u00a57894\u5104\", \"gross_profit\": 620593000000.0, \"gross_profit_fmt\": \"\u00a56206\u5104\", \"operating_income\": 54377000000.0, \"operating_income_fmt\": \"\u00a5544\u5104\", \"ebit\": 64584000000.0, \"ebit_fmt\": \"\u00a5646\u5104\", \"net_income\": 46433000000.0, \"net_income_fmt\": \"\u00a5464\u5104\", \"eps\": 163.76, \"operating_margin\": 6.89, \"total_assets\": 1386547000000.0, \"total_assets_fmt\": \"\u00a51.4T\", \"total_equity\": 841417000000.0, \"total_equity_fmt\": \"\u00a58414\u5104\", \"total_debt\": 187523000000.0, \"total_debt_fmt\": \"\u00a51875\u5104\", \"total_cash\": 265561000000.0, \"total_cash_fmt\": \"\u00a52656\u5104\", \"equity_ratio\": 60.68, \"de_ratio\": 0.22, \"current_ratio\": 1.95, \"operating_cf\": 30117000000.0, \"operating_cf_fmt\": \"\u00a5301\u5104\", \"investing_cf\": -10097000000.0, \"investing_cf_fmt\": \"-\u00a5101\u5104\", \"financing_cf\": -57809000000.0, \"financing_cf_fmt\": \"-\u00a5578\u5104\", \"free_cf\": 7148000000.0, \"free_cf_fmt\": \"\u00a571\u5104\", \"net_margin\": 5.88, \"roe\": 5.52, \"roa\": 3.35}, {\"year\": 2024, \"revenue\": 741751000000.0, \"revenue_fmt\": \"\u00a57418\u5104\", \"gross_profit\": 586417000000.0, \"gross_profit_fmt\": \"\u00a55864\u5104\", \"operating_income\": 53407000000.0, \"operating_income_fmt\": \"\u00a5534\u5104\", \"ebit\": 64211000000.0, \"ebit_fmt\": \"\u00a5642\u5104\", \"net_income\": 42407000000.0, \"net_income_fmt\": \"\u00a5424\u5104\", \"eps\": 147.86, \"operating_margin\": 7.2, \"total_assets\": 1393799000000.0, \"total_assets_fmt\": \"\u00a51.4T\", \"total_equity\": 875614000000.0, \"total_equity_fmt\": \"\u00a58756\u5104\", \"total_debt\": 159405000000.0, \"total_debt_fmt\": \"\u00a51594\u5104\", \"total_cash\": 304678000000.0, \"total_cash_fmt\": \"\u00a53047\u5104\", \"equity_ratio\": 62.82, \"de_ratio\": 0.18, \"current_ratio\": 2.37, \"operating_cf\": 55993000000.0, \"operating_cf_fmt\": \"\u00a5560\u5104\", \"investing_cf\": -25321000000.0, \"investing_cf_fmt\": \"-\u00a5253\u5104\", \"financing_cf\": -22720000000.0, \"financing_cf_fmt\": \"-\u00a5227\u5104\", \"free_cf\": 31170000000.0, \"free_cf_fmt\": \"\u00a5312\u5104\", \"net_margin\": 5.72, \"roe\": 4.84, \"roa\": 3.04}, {\"year\": 2023, \"revenue\": 744402000000.0, \"revenue_fmt\": \"\u00a57444\u5104\", \"gross_profit\": 566566000000.0, \"gross_profit_fmt\": \"\u00a55666\u5104\", \"operating_income\": 40040000000.0, \"operating_income_fmt\": \"\u00a5400\u5104\", \"ebit\": 47278000000.0, \"ebit_fmt\": \"\u00a5473\u5104\", \"net_income\": 55432000000.0, \"net_income_fmt\": \"\u00a5554\u5104\", \"eps\": 193.31, \"operating_margin\": 5.38, \"total_assets\": 1263350000000.0, \"total_assets_fmt\": \"\u00a51.3T\", \"total_equity\": 799959000000.0, \"total_equity_fmt\": \"\u00a58000\u5104\", \"total_debt\": 126105000000.0, \"total_debt_fmt\": \"\u00a51261\u5104\", \"total_cash\": 267350000000.0, \"total_cash_fmt\": \"\u00a52674\u5104\", \"equity_ratio\": 63.32, \"de_ratio\": 0.16, \"current_ratio\": 2.08, \"operating_cf\": -1772000000.0, \"operating_cf_fmt\": \"-\u00a518\u5104\", \"investing_cf\": -22723000000.0, \"investing_cf_fmt\": \"-\u00a5227\u5104\", \"financing_cf\": -24522000000.0, \"financing_cf_fmt\": \"-\u00a5245\u5104\", \"free_cf\": -36331000000.0, \"free_cf_fmt\": \"-\u00a5363\u5104\", \"net_margin\": 7.45, \"roe\": 6.93, \"roa\": 4.39}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 160.0}, {\"year\": 2023, \"amount\": 160.0}, {\"year\": 2024, \"amount\": 160.0}, {\"year\": 2025, \"amount\": 160.0}, {\"year\": 2026, \"amount\": 80.0}], \"latest\": 80.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-7482","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EISAI CO LTD - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4523\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/\",\"name\":\"EISAI CO LTD - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-19T16:34:59+00:00\",\"dateModified\":\"2026-08-23T04:47:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4523\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4523\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EISAI CO LTD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EISAI CO LTD - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4523\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/","url":"https:\/\/japanir.jp\/en\/company\/company-4523\/","name":"EISAI CO LTD - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-19T16:34:59+00:00","dateModified":"2026-08-23T04:47:42+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4523\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4523\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"EISAI CO LTD"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/7482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=7482"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=7482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}